Physician profile
Mohamed M Hegazi
NPI 1003206392
$380,373.88
in general payments reported to CMS, 2019-2025
56 companies · $141K in 2025
The $141K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,007 · 2020: $438 · 2021: $12K · 2022: $48K · 2023: $72K · 2024: $104K · 2025: $141K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $240K · Travel and Lodging: $39K · Consulting Fee: $22K · Food and Beverage: $16K · Education: $66.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $240,395.00 |
| Travel and Lodging | $38,715.87 |
| Consulting Fee | $21,668.10 |
| Food and Beverage | $15,858.09 |
| Education | $66.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $152,890.33 | 2021-2025 | Brukinsa |
| E.R. Squibb & Sons, L.L.C. | $76,424.74 | 2019-2025 | Onureg, Breyanzi, Reblozyl |
| Beone Medicines USA, INC. | $45,534.07 | 2025 | Brukinsa, Tevimbra |
| Syndax Pharmaceuticals, INC. | $36,724.45 | 2025 | Revuforj |
| Janssen Biotech, INC. | $18,702.89 | 2019-2025 | Carvykti, Rybrevant, Talvey |
| Glaxosmithkline, LLC. | $15,437.67 | 2022-2025 | Ojjaara |
| Incyte Corporation | $9,250.12 | 2019-2025 | Niktimvo, Jakafi, Monjuvi |
| Abbvie INC. | $3,945.67 | 2022-2025 | |
| Geron Corporation | $3,718.42 | 2024-2025 | Rytelo |
| Legend Biotech USA INC. | $3,414.96 | 2024-2025 | Carvykti |
| Jazz Pharmaceuticals INC. | $2,854.12 | 2019-2024 | |
| Celgene Corporation | $2,721.89 | 2019-2025 | Reblozyl, Breyanzi, Pomalyst |
| Adaptive Biotechnologies Corporation | $1,874.18 | 2020-2025 | Clonoseq |
| Genzyme Corporation | $717.03 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $708.65 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $596.95 | 2023-2025 | |
| Amgen INC. | $470.18 | 2019-2023 | Kyprolis, Lumakras, Xgeva |
| Novartis Pharmaceuticals Corporation | $423.97 | 2019-2025 | |
| Astellas Pharma US INC | $417.41 | 2019-2025 | Cresemba, Xospata, Vyloy |
| Kite Pharma, INC. | $343.46 | 2021-2025 | Yescarta |
| Morphosys, US INC. | $330.10 | 2023 | Monjuvi |
| Genentech USA, INC. | $279.89 | 2019-2025 | Venclexta, Polivy, Lunsumio |
| Astrazeneca Pharmaceuticals Lp | $251.21 | 2019-2025 | Enhertu, Tagrisso, Wainua |
| Sanofi-Aventis U.S. LLC | $230.76 | 2023-2025 | |
| Genmab U.S., INC. | $204.09 | 2024-2025 | Epkinly |
| Iovance Biotherapeutics, INC. | $196.28 | 2024 | Amtagvi |
| Daiichi Sankyo INC. | $168.68 | 2024-2025 | Vanflyta, Injectafer |
| Alexion Pharmaceuticals, INC. | $164.86 | 2019-2024 | Ultomiris |
| Pfizer INC. | $156.03 | 2019-2024 | |
| Ipsen Biopharmaceuticals, INC | $141.92 | 2024-2025 | Tazverik, Onivyde |
| Seagen INC. | $95.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $91.76 | 2019-2025 | Lynozyfic, Libtayo |
| Merck Sharp & Dohme LLC | $88.30 | 2019-2025 | Reblozyl, Keytruda |
| Pharmacyclics LLC, An Abbvie Company | $74.55 | 2019-2023 | Imbruvica |
| Takeda Pharmaceuticals U.S.A., INC. | $71.92 | 2019-2025 | Iclusig, Fruzaqla |
| Sobi, INC | $67.71 | 2024-2025 | |
| Stemline Therapeutics INC. | $59.33 | 2024-2025 | Orserdu, Elzonris |
| Lilly USA, LLC | $57.14 | 2024 | Jaypirca |
| Eusa Pharma (US) LLC | $54.55 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.87 | 2019-2025 | |
| Pharmaessentia USA Corporation | $42.65 | 2023-2025 | Besremi |
| Blueprint Medicines Corporation | $40.05 | 2023-2024 | Ayvakit |
| Verastem, INC. | $37.98 | 2019-2020 | |
| Foundation Medicine, INC. | $34.38 | 2019 | |
| Cti Biopharma Corp. | $30.14 | 2023 | Vonjo |
| Karyopharm Therapeutics INC. | $28.07 | 2020-2024 | Xpovio |
| Secura Bio, INC. | $23.87 | 2025 | Copiktra |
| Accord Healthcare, INC. | $22.71 | 2025 | |
| Agios Pharmaceuticals, INC. | $21.94 | 2025 | Pyrukynd |
| Gilead Sciences, INC. | $20.28 | 2023 | |
| Mirati Therapeutics, INC. | $19.29 | 2023 | Krazati |
| Puma Biotechnology, INC. | $15.92 | 2024 | |
| Aurobindo Pharma USA, INC. | $12.79 | 2019 | |
| Coherus Oncology, INC. | $12.78 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $10.92 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Hegazi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.